Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

histamine dihydrochloride and IL-2

Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg \[16,400 IU/kg\] body weight twice daily for 10, 21 day cycles

Trial Locations (1)

Sahlgrenska Academy, University of Gothenburg, Gothenburg